International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Primary objectives: * Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) * Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)

Trial Details

NCT ID

NCT04043494

Phase

PHASE3

Sponsor

University Hospital Muenster

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Cyclophosphamide
Cytarabine
Dexamethasone
Daunorubicin
Doxorubicin
Ifosfamide

Locations (sample)

Graz, Austria|47.06733,15.44197
Innsbruck, Austria|47.26266,11.39454
Linz, Austria|48.30639,14.28611
Salzburg, Austria|47.79941,13.04399
Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

newly diagnosed lymphoblastic lymphoma
age \<18 years
patient enrolled in a participating center
written informed consent of patient (\>14 years of age or according to local law and regulation) and parents to trial participation and transfer an…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →